| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.3 | 0.1 |
| Gross profit | -0.0 | 0.1 |
| Profit before tax | -6.3 | -7.1 |
| Net income | -6.3 | -5.9 |
| EPS (diluted, $ a share) | $-1.01 | $-4.66 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +94.6% |
|---|---|
| Gross margin | -7.2% |
10-Q filed with the SEC, NASDAQ: CODX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Co-Diagnostics, Inc.: key numbers
- Share price
- $0.2249Close, Nov 16
- Market cap
- $2.36M
- Shares outstanding
- 10.51MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Co-Diagnostics, Inc.
All →Co-Diagnostics Shareholder Meeting
Co-Diagnostics held a court-ordered special meeting of shareholders on November 13, 2026, where shareholders elected five directors and approved an amendment to the 2025 Equity Incentive Plan. The amendment increases the number of shares authorized for issuance under the plan by 2,000,000 shares, bringing the total maximum to 2,223,333 shares. Shareholders also approved a non-binding advisory resolution regarding executive compensation.
Co-Diagnostics Financial Results
Co-Diagnostics reported Q3 2026 financial results, highlighting a 12% year-over-year reduction in operating expenses and the submission of a 510(k) premarket notification to the FDA for its Flu A/B & RSV test. The company also expanded its platform capabilities through a collaboration with ReadyGo Diagnostics and the launch of cloud infrastructure in India.
- Term
- Q3 2026
Co-Diagnostics Shareholder Meeting
Co-Diagnostics, Inc. reconvened its 2026 Annual Meeting of Stockholders on October 14, 2026, but was unable to transact business because a quorum was not present. The company determined not to adjourn the meeting again and intends to seek stockholder approval for the proposals at a future special meeting.
Co-Diagnostics $3.1M Debt Financing with J.J. Astor & Co.
Co-Diagnostics, Inc. entered into a loan agreement with J.J. Astor & Co. for an aggregate principal funding amount of up to $3.1 million, with an initial $2.1 million funded at closing. The debt is structured as senior secured convertible installment promissory notes with a 1.35x factor rate, payable in 30 weekly installments and secured by substantially all company assets.
- Value
- $3.1M
- Counterparty
- J.J. Astor & Co.
- Term
- 30 weeks
Co-Diagnostics $3.1M Debt Financing with J.J. Astor & Co.
Co-Diagnostics entered into a senior secured convertible loan agreement with J.J. Astor & Co. for an aggregate principal funding amount of up to $3.1 million. The initial funding of $2.1 million resulted in a promissory note with an original principal amount of $2.835 million, reflecting a 1.35x factor rate, and is secured by substantially all of the company's assets.
- Value
- $3.1M
- Counterparty
- J.J. Astor & Co.
- Term
- 30 weeks
Co-Diagnostics Shareholder Meeting
Co-Diagnostics, Inc. announced that its 2026 Annual Meeting of Stockholders has been adjourned for a third time to October 14, 2026, due to a failure to achieve a quorum. The company was unable to transact any business at the original September 3 meeting or the subsequent adjournments on September 24 and September 30. Stockholders of record as of the original July 14, 2026 record date remain eligible to vote at the reconvened meeting.